Elicio Therapeutics, Inc. Amortization of Debt Discount (Premium)
Elicio Therapeutics, Inc. (ELTX) reported Amortization of Debt Discount (Premium) of $128.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-13
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2026-06-30 was $60.00K.
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2026-03-31 was $68.00K, a 94.29% increase year-over-year.
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $182.00K, a 271.43% increase year-over-year.
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2025 was $217.00K, a 189.33% increase from fiscal 2024.
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2024 was $75.00K.
- Elicio Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2023 was $0.00.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $128.00K 10-Q · filed 2026-08-13 | $310.00K derived: sum of 3 quarters · filed 2026-08-13 | $310.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $68.00K 10-Q · filed 2026-05-11 | $250.00K derived: sum of 2 quarters · filed 2026-05-11 | $250.00K derived: sum of 3 quarters · filed 2026-05-11 | $250.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $182.00K derived: sum of 2 quarters · filed 2026-03-12 | $182.00K derived: sum of 3 quarters · filed 2026-08-13 | $217.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $35.00K 10-Q · filed 2025-11-13 | $84.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $35.00K 10-Q · filed 2026-08-13 | $84.00K derived: sum of 3 quarters · filed 2026-08-13 | $110.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $35.00K 10-Q · filed 2026-05-11 | $84.00K derived: sum of 2 quarters · filed 2026-05-11 | $110.00K derived: sum of 3 quarters · filed 2026-05-11 | $110.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $75.00K derived: sum of 2 quarters · filed 2026-03-12 | $75.00K derived: sum of 3 quarters · filed 2026-03-12 | $75.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $26.00K derived: sum of 2 quarters · filed 2025-11-13 | $26.00K 10-Q · filed 2025-11-13 | $26.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |